We would love to hear your thoughts about our site and services, please take our survey here.
I no longer work but thank you for your concern :-). There is no comparison between 4d and avacta but clear comparisons between shareholder bases and attraction of actors with ulterior motives. I'm sure many decent people have lost money here already because of their actions all whilst the good ship avacta sails serenely on. We'd do best to deter and ultimately remove such actors from Avacta shareholder list, which is unfortunately an incredibly immature one.
Many 4D holders hurting, commiserations to them. Whilst not related to AVCT as mentioned, reading through their board should serve as a stark reminder that lots will have invested heavily here, hopefully very few off the back of rampers. Don't give the rampers or derampers time of day, green box them. Hate to see them having potentially life changing impacts on PIs. Bottom feeders of lowest order!
As always thanks to those contributing to real discussion here. Have a great weekend all.
BITL, I believe what he said there re deals was true. What I also believe is he was naive and was not the greatest at Comms and expectations management as he should have realised that it wasn't as much in AVCTs control as he suggested. Something we all found out about.
There's a big difference between the LFT being rogered by UKGOV and the current trial but yes we should hope he has learnt lessons from LFT debacle. Let's not slip into thinking he's a liar or misleading us intentionally, I see no reason to believe that - quite the opposite he seems a man of integrity.
Like the Mos Eisley cantina in here today. If you find it getting to you just log off LSE, close Twitter and enjoy the weather. Stick to your research, nothing to be gained from FUD and potentially everything to lose.
GLA - except you (you know who yous are)
You have it on good authority something is happening Monday, you've spend an afternoon reading about the co, and are hoping for £1.30 cop Mon?
I'd spend another afternoon or three reading! (or be more discerning in your friendships)
Seems that the potential for LFT is beyond what is superficially nose/throat.
"Applications for the lateral flow assay, such as detection of cardiac biomarkers, biothreats and single cell signals, have driven developments in assay design. "
https://avacta.com/2017-04-10/
Wouldn't rule it out! Although past experience..
"Avacta Group has not applied or agreed to have any of its securities (including its AIM securities) admitted or traded on any other exchanges or trading platforms."
https://avacta.com/investors/key-information/
Was looking at a city centre property yesterday to add to rental income. Good yield, upcoming area with reliable tenants. Got home and plotted five months worth of offers on Excel and some of the lines looked a bit noddy so decided against buying it.
I ask this purely out of ignorance - could someone lay out for a simpleton why this is positive? I'd have thought you'd want to keep them unvested for as long as possible, and thereby avoid any admin/taxes/fees, if you thought the future was rosy. Conversely if you wanted to cash in you'd have to exercise the option and sell? Is there a CGT advantage to exercising before a rise in price or something? or perhaps it's purely psychological and employees think good times ahead I want my shares?
As a disclaimer I'm very positive and longer than John Silver myself!
Difference for me Mac is that I don't think he did over promise at any point (but we will see). It was a highly professional presentation, which whilst optimistic, didn't over step the line. Nice to see that AS is growing as the company does.
Only reason to write it off is if your only goal was a bumper COVID test order. Long term they've proved the viability of their diagnostics platform. Lessons to be learnt from COVID test from commercial pov I'm sure and we'd all have loved the cash but the main objective seems to have been achieved. I'm sure Medusa had an eye for more than COVID.
They can both be right. I'm sure we are able to produce a test in response to new variants in the future, which remains an opportunity of limited scope,but it's increasingly clear we have missed the COVID test lollapalooza.